CJC-1295 (no dac) 10mg + Ipamorelin 10mg

CJC-1295 No DAC (MOD GRF 1-29) / Ipamorelin 10 mg / 10 mg is a high-purity dual-component lyophilized peptide research blend supplied exclusively for scientific investigation and controlled laboratory experimentation.

For research use only — not for human or veterinary use.

Product Overview

CJC-1295 No DAC (MOD GRF 1-29) / Ipamorelin combines two distinct synthetic peptide research compounds within a single lyophilized preparation. The blend is designed for controlled scientific investigations involving peptide biology, receptor interactions, molecular signalling and biochemical communication pathways.

The CJC-1295 component contained in this research blend is the No DAC form and is identified in the independent analytical report as MOD GRF (1-29). The designation CJC-1295 No DAC is commonly used for this research peptide, while MOD GRF (1-29) provides the more specific identification used within the laboratory analysis.

This distinction is important because CJC-1295 No DAC (MOD GRF 1-29) is not the DAC-containing form of CJC-1295. This product contains MOD GRF (1-29) together with Ipamorelin and does not contain a Drug Affinity Complex (DAC).

The preparation is labelled as containing 10 mg of CJC-1295 No DAC (MOD GRF 1-29) and 10 mg of Ipamorelin. Independent third-party laboratory testing separately quantified both peptide components. Ipamorelin assay content was measured at 10.97 mg, while MOD GRF (1-29) assay content was measured at 10.19 mg.

Both components were also independently evaluated for chromatographic purity. Ipamorelin achieved purity greater than 99.8 percent and MOD GRF (1-29) achieved purity greater than 99.8 percent.

In addition to assay and purity determination, each peptide component underwent individual identity verification using FTIR spectrum analysis, HPLC retention time comparison and mass spectrometry. This provides substantially more analytical information than a single overall purity measurement for the combined blend.

Dual-Peptide Research Blend

Multi-component peptide research preparations require particularly comprehensive analytical verification because confirming the overall composition of a blend does not necessarily establish the quantity, purity and identity of each individual constituent.

For this reason, the CJC-1295 No DAC (MOD GRF 1-29) and Ipamorelin components within this production batch were evaluated separately.

• CJC-1295 No DAC (MOD GRF 1-29): 10.19 mg assay content with purity greater than 99.8 percent
• Ipamorelin: 10.97 mg assay content with purity greater than 99.8 percent

Both peptides were additionally subjected to individual FTIR identification, HPLC retention time verification and molecular ion mass identification.

This separate analytical verification provides researchers with detailed information concerning both stated components rather than relying on a general purity specification for the complete peptide mixture.

CJC-1295 No DAC (MOD GRF 1-29) Overview

The CJC-1295 component within this preparation is specifically the No DAC form, analytically identified as MOD GRF (1-29).

MOD GRF (1-29) is a synthetic peptide research compound investigated within experimental models involving peptide-receptor interactions, endocrine molecular signalling and intracellular communication pathways.

The term CJC-1295 No DAC is frequently used within peptide research to distinguish MOD GRF (1-29) from the longer-acting DAC-containing CJC-1295 research compound.

The product described here specifically contains CJC-1295 No DAC / MOD GRF (1-29). It should therefore not be confused with CJC-1295 with DAC.

Independent laboratory analysis of this production batch measured the MOD GRF (1-29) component at 10.19 mg, with chromatographic purity reported as greater than 99.8 percent.

Identity was independently evaluated through FTIR spectrum analysis, HPLC retention time verification and molecular ion mass identification.

Ipamorelin Overview

Ipamorelin is a synthetic peptide research compound widely investigated within experimental peptide science involving receptor biology, molecular signalling and biochemical communication pathways.

Within this dual-component research preparation, Ipamorelin was independently quantified and characterised rather than being evaluated solely as part of the combined peptide mixture.

Independent laboratory analysis measured an Ipamorelin assay content of 10.97 mg, with chromatographic purity reported as greater than 99.8 percent.

Identity assessment included FTIR spectrum analysis, HPLC retention time verification and mass spectrometry, providing multiple independent analytical parameters for characterising the Ipamorelin component.

Scientific and Research Context

Modern peptide science increasingly relies on highly characterised synthetic research compounds for investigating complex molecular signalling systems under controlled laboratory conditions.

Dual-component preparations provide researchers with an opportunity to investigate two distinct peptide structures within the same experimental system while retaining the ability to analytically characterise each component individually.

This makes comprehensive testing particularly important. A single purity result for an entire blend provides limited information regarding the identity, quantity and purity of the individual constituents.

For this CJC-1295 No DAC (MOD GRF 1-29) / Ipamorelin preparation, independent third-party testing provides individual assay, purity and identity measurements for both peptide components, together with microbiological, bacterial endotoxin and elemental impurity analysis of the production batch.

Mechanistic Focus in Research

Within controlled laboratory environments, CJC-1295 No DAC (MOD GRF 1-29) and Ipamorelin may be investigated in experimental models involving peptide-mediated receptor signalling and molecular communication pathways.

Potential areas of scientific investigation include:

• Peptide-receptor interaction studies
• Receptor-mediated signalling research
• Endocrine molecular signalling investigations
• Intracellular communication pathway analysis
• Dual-peptide interaction studies
• Comparative peptide research
• Biochemical regulatory pathway investigations
• Molecular signalling studies
• Controlled in vitro peptide experimentation

These areas describe scientific research contexts only and do not represent therapeutic, diagnostic or clinical applications.

Analytical Verification (COA)

This production batch of CJC-1295 No DAC (MOD GRF 1-29) / Ipamorelin underwent comprehensive independent third-party laboratory analysis by Liquilabs s.r.o. Czechia.

The analytical programme separately evaluates the two peptide components while additionally providing microbiological, bacterial endotoxin and elemental impurity data for the tested production batch.

Batch: GF-CJCIPA10/10-B243

• Labelled CJC-1295 No DAC (MOD GRF 1-29) Content: 10 mg
• Measured MOD GRF (1-29) Assay: 10.19 mg
• MOD GRF (1-29) Purity: greater than 99.8 percent
• MOD GRF (1-29) FTIR Identification: 995
• MOD GRF (1-29) HPLC Retention Time: 0.993
• MOD GRF (1-29) Molecular Ion Mass: 3367 Da
• Labelled Ipamorelin Content: 10 mg
• Measured Ipamorelin Assay: 10.97 mg
• Ipamorelin Purity: greater than 99.8 percent
• Ipamorelin FTIR Identification: 996
• Ipamorelin HPLC Retention Time: 0.992
• Ipamorelin Molecular Ion Mass: 711 Da
• Bacterial Endotoxins: 0.062 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

The analytical results demonstrate that both stated peptide components were separately quantified and independently identified within the tested production batch.

Assay and Purity Verification

Assay content and chromatographic purity represent two separate analytical measurements and provide different information regarding a peptide research compound.

Assay analysis determines the measured quantity of the target compound within the tested material. Independent laboratory analysis measured 10.19 mg of CJC-1295 No DAC (MOD GRF 1-29) and 10.97 mg of Ipamorelin.

Chromatographic purity was separately evaluated for each component, with greater than 99.8 percent purity reported for both MOD GRF (1-29) and Ipamorelin.

Separately determining assay and purity for both components provides considerably greater analytical transparency than reporting a single combined purity percentage for the complete research blend.

Identity Verification

Both peptide components underwent individual identity verification using complementary analytical techniques.

For CJC-1295 No DAC (MOD GRF 1-29), FTIR spectrum identification produced a reported result of 995 and HPLC retention time identification measured 0.993.

For Ipamorelin, FTIR spectrum identification produced a reported result of 996 and HPLC retention time identification measured 0.992.

The independent analysis of each peptide provides multiple analytical data points supporting the identification and characterisation of both components within the research blend.

Mass Spectrometry Analysis

Mass spectrometry provides additional molecular identity information by determining the molecular ion mass associated with each research compound.

For this production batch, mass spectrometry identified:

• CJC-1295 No DAC (MOD GRF 1-29): molecular ion mass of 3367 Da
• Ipamorelin: molecular ion mass of 711 Da

The separate molecular ion mass identification of both components adds an additional level of analytical characterisation to the dual-component preparation.

Microbiological Testing

Microbiological analysis was performed as part of the independent quality assessment of the tested production batch.

The following results were reported:

• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

No colony-forming units were detected for either of the reported microbiological parameters in the analysed sample.

Microbiological testing complements the peptide-specific assay, purity and identity measurements and contributes to the broader analytical characterisation of the research material.

Bacterial Endotoxin Analysis

Bacterial endotoxin testing provides an additional analytical parameter for evaluating lyophilized research materials.

For this CJC-1295 No DAC (MOD GRF 1-29) / Ipamorelin production batch, bacterial endotoxin analysis produced a result of 0.062 EU/mg.

The laboratory Certificate of Analysis reports an acceptance range of 0–0.5 EU/mg for this parameter.

This measurement forms part of the comprehensive independent analytical profile for the tested production batch.

Elemental Impurity Testing

Independent elemental impurity screening was performed for a range of potentially relevant elemental contaminants.

The analytical programme included:

• Arsenic
• Cadmium
• Mercury
• Lead
• Nickel
• Vanadium
• Cobalt

Each tested elemental impurity was reported at less than 0.001 ppm.

Elemental impurity screening provides an additional analytical quality parameter alongside assay determination, purity analysis, identity verification, mass spectrometry, microbiological analysis and bacterial endotoxin testing.

Research Applications

CJC-1295 No DAC (MOD GRF 1-29) / Ipamorelin is supplied exclusively for controlled scientific investigation and may be utilised in experimental laboratory models involving peptide biology and molecular signalling.

Potential research contexts include:

• Dual-peptide characterisation studies
• Peptide-receptor interaction research
• Receptor signalling investigations
• Endocrine molecular pathway research
• Intracellular communication studies
• Comparative peptide analysis
• Biochemical pathway investigations
• Molecular interaction research
• Controlled in vitro peptide studies

These applications refer exclusively to scientific and laboratory investigation.

Comprehensive Dual-Component Verification

A particularly important analytical characteristic of this production batch is the separate verification of both peptide components.

Independent third-party analysis includes:

• Individual assay determination for CJC-1295 No DAC (MOD GRF 1-29)
• Individual assay determination for Ipamorelin
• Individual chromatographic purity assessment for MOD GRF (1-29)
• Individual chromatographic purity assessment for Ipamorelin
• Separate FTIR identity analysis for both peptides
• Separate HPLC retention time verification for both peptides
• Separate molecular ion mass identification for both peptides
• Bacterial endotoxin analysis
• Total Aerobic Microbial Count testing
• Total Yeast and Mold Count testing
• Elemental impurity screening

This comprehensive approach provides researchers with detailed analytical information concerning each constituent rather than treating the preparation as a single unidentified peptide mixture.

Grail Formula Quality

Grail Formula places particular emphasis on independent third-party laboratory testing, transparent batch documentation and comprehensive multi-parameter analytical verification.

For dual-component research preparations, this means evaluating the individual peptide constituents wherever supported by the analytical methodology rather than relying solely on a general purity claim for the complete blend.

For this production batch, Liquilabs s.r.o. Czechia separately quantified and characterised CJC-1295 No DAC (MOD GRF 1-29) and Ipamorelin while additionally evaluating bacterial endotoxins, microbiological quality and elemental impurities.

The resulting Certificate of Analysis provides transparent batch-specific laboratory data that researchers can review directly when evaluating the analytical characteristics of the supplied research material.

When You Choose Grail Formula

When selecting Grail Formula, researchers receive research compounds supported by independent analytical documentation and complete batch-specific traceability.

Our quality approach focuses on measurable laboratory results rather than unsupported purity claims. For this dual-component preparation, both stated peptide components have been individually quantified, independently assessed for chromatographic purity and evaluated using multiple identity measurements.

CJC-1295 No DAC (MOD GRF 1-29) was independently measured at 10.19 mg with purity greater than 99.8 percent, while Ipamorelin was independently measured at 10.97 mg with purity greater than 99.8 percent.

Both components were additionally verified through FTIR spectrum analysis, HPLC retention time comparison and molecular ion mass identification.

The complete batch-specific Certificate of Analysis allows researchers to review the underlying analytical results directly.

Storage and Laboratory Handling

CJC-1295 No DAC (MOD GRF 1-29) / Ipamorelin is supplied in lyophilized form for controlled laboratory research. Appropriate laboratory storage procedures should be followed to preserve the integrity of the research material.

The material should be handled only by qualified research personnel using established laboratory procedures appropriate for synthetic peptide research compounds.

Any preparation or experimental handling should take place exclusively within a suitable controlled laboratory environment and in accordance with the requirements of the intended research protocol.

Research Use Limitation

• Intended solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for self-administration
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not intended to prevent or treat any disease
• Not permitted for clinical administration
• For research use only

CJC-1295 No DAC (MOD GRF 1-29) / Ipamorelin 10 mg / 10 mg is supplied exclusively as a research compound. All product information and analytical documentation are provided solely for scientific and laboratory purposes.

• Dual-component CJC-1295 (MOD GRF 1-29) and Ipamorelin research blend
• Independently analysed by Liquilabs s.r.o. Czechia
• Ipamorelin assay content verified at 10.97 mg
• MOD GRF (1-29) assay content verified at 10.19 mg
• Ipamorelin purity greater than 99.8 %
• MOD GRF (1-29) purity greater than 99.8 %
• Ipamorelin FTIR identification result of 996
• MOD GRF (1-29) FTIR identification result of 995
• Ipamorelin HPLC retention time confirmed at 0.992
• MOD GRF (1-29) HPLC retention time confirmed at 0.993
• Ipamorelin molecular ion mass identified at 711 Da
• MOD GRF (1-29) molecular ion mass identified at 3367 Da
• Bacterial endotoxin level measured at 0.062 EU/mg
• Total Aerobic Microbial Count measured at 0 CFU/g
• Total Yeast and Mold Count measured at 0 CFU/g
• Arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt all measured below 0.001 ppm
• Both peptide components individually verified for assay, purity and identity
• Complete batch-specific third-party analytical documentation
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.